Valuation: CSL Limited

Market Cap 60.66B 54.2B 50.57B 45.93B 86.51B 5,868B 87.16B 608B 237B 2,985B 228B 223B 9,594B P/E 2027 *
20.8x
P/E 2028 * 18.9x
Enterprise Value 69.9B 62.45B 58.27B 52.92B 99.68B 6,762B 100B 700B 274B 3,439B 262B 257B 11,055B EV / Sales 2027 *
4.44x
EV / Sales 2028 * 4.26x
Free-Float
99.97%
Yield 2027 *
2.37%
Yield 2028 * 2.51%
1 day-0.34%
1 week-1.55%
Current month-1.55%
1 month+4.73%
3 months+46.30%
6 months+29.26%
Current year+5.05%
1 week 174.67
Extreme 174.67
187
1 month 165.79
Extreme 165.79
187
Current year 90
Extreme 90
187
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 A Free

Director

523 0.0001%
8/26/26 A Free 317 0.0001% -
8/26/26 A Free

Director

1,586 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%-1.55%-11.67%-28.44% 59.74B
+2.70%+2.73%+40.91%+110.31% 1,032B
+1.44%-2.38%+36.83%+63.95% 614B
+1.75%+3.73%+16.55%+83.05% 471B
+0.60%-1.73%+62.98%+37.46% 350B
+2.92%+3.12%+24.78%+45.10% 337B
+2.42%+0.05%+14.13%+35.80% 268B
+1.86%-0.81%-4.69%+12.20% 246B
+2.60%-2.00%+39.77%+54.44% 218B
+1.82%-1.48%+25.75%+96.48% 179B
Average +1.28%-1.25%+24.53%+51.04% 377.46B
Weighted average by Cap. +0.79%-0.50%+31.32%+69.02%

Financials

2027 *2028 *
Net sales 15.76B 14.08B 13.13B 11.93B 22.47B 1,524B 22.64B 158B 61.67B 775B 59.15B 57.87B 2,492B 16.32B 14.58B 13.6B 12.35B 23.27B 1,578B 23.44B 163B 63.85B 803B 61.25B 59.93B 2,580B
Net income 2.82B 2.52B 2.35B 2.14B 4.02B 273B 4.05B 28.27B 11.04B 139B 10.59B 10.36B 446B 3.15B 2.81B 2.62B 2.38B 4.49B 305B 4.52B 31.54B 12.32B 155B 11.82B 11.57B 498B
Net Debt 9.23B 8.25B 7.7B 6.99B 13.17B 893B 13.26B 92.49B 36.13B 454B 34.66B 33.91B 1,460B 8.92B 7.97B 7.44B 6.75B 12.72B 863B 12.81B 89.35B 34.91B 439B 33.49B 32.76B 1,411B
Projected Income Statement - Annual - CSL Limited
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
08/10/26 A$181.37 -0.34% 167,723
07/10/26 A$181.99 +1.85% 1,408,941
06/10/26 A$178.68 +0.95% 928,340
05/10/26 A$176.99 +0.94% 536,607
02/10/26 A$175.35 -1.62% 1,050,259
Trader
Investor
Global
Quality
ESG MSCI
A
Ratings Surperformance© - CSL Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
126.67USD
Average target price
128.86USD
Spread / Average Target
+1.73%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CSL Limited